Company Overview
SeaStar Medical Holding Corporation operates as a commercial-stage medical device company focused on the United States market, where it develops a proprietary platform therapy designed to mitigate the consequences of hyperinflammation on vital organs. The company specifically offers the selective cytopheretic device (SCD), which functions as a disease-modifying device intended to address critical organ damage. This entity functions within the Healthcare sector and the Biotechnology industry, positions that characterize it as a developer of specialized medical technologies rather than a provider of broad consumer goods or services. The company currently maintains a market capitalization of $10.41M and generates annual revenue of $1.23M, while the employee count is not publicly disclosed in available data. These financial metrics indicate that SeaStar Medical is a small-cap biotechnology firm with a limited revenue base relative to its market valuation, suggesting a high valuation multiple that is typical for early-stage or commercial-stage device companies seeking to scale their proprietary therapies before achieving widespread commercial adoption.
Financial Health
The company reports a trailing twelve-month revenue of $1.23M alongside a net income of $-12,150,000, while EBITDA data is not available for calculation. The substantial gap between the modest revenue figure and the significant net loss reveals a cost structure characterized by high operating expenses, likely driven by research and development activities, clinical trial costs, and general administrative overheads common in the biotechnology industry. Free cash flow stands at $-10,313,750, which indicates that the company is currently burning cash to fund its operations and development pipeline, thereby limiting its immediate financial flexibility without access to external capital markets or existing cash reserves. The gross margin is reported at 95.7%, indicating that the cost of goods sold is very low relative to revenue, whereas the operating margin is -718.1% and the profit margin is 0.0%, reflecting the intense expense burden relative to sales volume. On the balance sheet, the company holds $11.98M in cash against total debt of $525,000, resulting in a debt-to-equity ratio of 5.04, which suggests a leveraged position where equity is relatively small compared to debt obligations. Despite the leverage, the current ratio of 3.63 indicates strong short-term liquidity, as the company possesses more than three times the current assets necessary to cover its current liabilities. Return on Equity is -295.2% and Return on Assets is -80.9%, metrics that reveal that management has not yet generated positive returns on the capital invested, a status typical for companies in the development or commercial-stage phases where losses are expected to persist until product revenue scales significantly.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is -1.07, a discrepancy that implies the market is pricing in future earnings potential that does not yet align with current financial performance. The price-to-book ratio stands at 1.01, suggesting that the market values the company at approximately its book value, which often occurs when future growth prospects are uncertain or when the company is loss-making. The price-to-sales ratio is 8.44, a high multiple that indicates the market is willing to pay a significant premium for every dollar of sales, likely betting on the success of the selective cytopheretic device or future product approvals. The EV/EBITDA metric is not applicable, further limiting traditional earnings-based valuation comparisons given the company's lack of positive EBITDA. The stock's 52-week high is $25.70 and the 52-week low is $2.09, providing a range within which the security has traded over the past year. Without a specific current price provided in the facts, the precise percentage distance from the high or low cannot be calculated, but the wide range demonstrates significant price volatility common in small-cap biotechnology stocks. The beta value is not available, preventing a direct comparison of the stock's price volatility relative to the broader market index based on the provided data points.
Growth & Income
Revenue growth year-over-year is reported at 526.9%, while earnings growth is not applicable due to the company's negative earnings history. The disparity between revenue growth and the inability to calculate earnings growth implies that while sales are expanding rapidly, the cost structure has not yet scaled efficiently enough to generate profitability, a common pattern in capital-intensive medical device development. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, indicating that all available cash flow is reinvested back into the business to fund ongoing research, development, and commercialization efforts. The overall growth and income profile reflects a high-growth, zero-income trajectory where shareholder returns are entirely dependent on capital appreciation rather than dividend income or earnings yield. This profile requires significant patience from market participants who must rely on future product milestones and regulatory approvals to transition the company from a cash-burning entity to a profitable one.